

Oslo Börs Admits Shares in SCN To Listing On Oslo Axess

At a Board meeting today, the Board of Oslo Börs resolved to admit the shares in Scandinavian Clinical Nutrition i Sverige AB to listing on Oslo Axess.

More information about the resolution and the listing conditions can be found in the press release from Oslo Börs at www.oslobors.no.

For further information:

Ulf Söderberg, CEO, ulf.soderberg@scnutrition.com, +46 708 13 22 81

Scandinavian Clinical Nutrition AB (publ) works in R&D and sales of scientifically documented products within the field of nutrition (nutraceuticals). Established in 2006, SCN maintains a product portfolio with established trademarks, such as CUUR, Membraseven, Coldizin, Immulina and Ledactin. Core competence and strategic alliances, within both R&D and sales, in combination with innovative and scientifically documented products, create the right conditions for profitable growth both in Sweden and in the company's export markets. The SCN share is listed for trade on NGM Nordic MTF since December 6, 2006.